Acs Omega

AUG 14, 2026 · JOURNAL ARTICLE

Crocetin HaltsTumorigenesis in Metastatic BreastCancer via Disrupting CYP2J2/EET Axis

Acs Omega

Mechanistic and exploratory preclinical work using in silico, in vitro, and in vivo models to propose a novel pathway; no clinical trial data, no hard clinical endpoints, and findings remain at proof-of-concept stage.

AUG 13, 2026 · JOURNAL ARTICLE

Discovery of Bis-ThioureaDerivatives as Human DNATopoisomerase IIα Inhibitors with Potent Anticancer Effects

Acs Omega

Early-stage in vitro and in silico discovery study of a novel compound with no human trials, clinical outcomes, or comparative efficacy data reported.

AUG 11, 2026 · JOURNAL ARTICLE

FAP-Inhibitor Homodimers with Engineered Linker-SpacerUnits: Toward Optimized Radiopharmaceuticals

Acs Omega

This is preclinical chemical and radiochemical characterization of novel compounds with in vitro binding and cell studies, lacking in vivo efficacy data or clinical translation to support therapeutic claims.

AUG 10, 2026 · JOURNAL ARTICLE

Development andCharacterization of Celecoxib-Loaded Soluplus/Zein Composite NanoparticlesCoated with Chitosan for Pulmonary Drug Delivery

Acs Omega

In vitro and ex vivo characterization of a novel nanoparticle formulation with no in vivo efficacy or safety data in animals or humans; demonstrates feasibility of the drug delivery system but requires substantial preclinical and clinical validation before clinical relevance can be assessed.